-
2 weeks ago | 
ajmc.com | Maggie L. Shaw |Frederick Locke
The phase 1 ALPHA (NCT03939026) and phase 1/2 ALPHA2 (NCT04416984) trials are investigating cemacabtagene ansegedleucel (cema-cel), an allogeneic chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory large B-cell lymphoma. Findings from these 2 trials comprise the foundation for the phase 2 ALPHA3 (NCT06500273) trial, which is evaluating first-line consolidation treatment with cema-cel in patients with a low disease burden.
-
1 month ago | 
ajmc.com | Maggie L. Shaw |Frederick Locke
Cemacabtagene ansegedleucel (cema-cel; Allogene Therapeutics) is an allogeneic chimeric antigen receptor (CAR) T-cell therapy currently being investigated for relapsed/refractory large B-cell lymphoma, a type of non-Hodgkin lymphoma, in the ALPHA (NCT03939026) and ALPHA2 (NCT04416984) clinical trials. Lead investigator Frederick L.
-
2 months ago | 
ajmc.com | Maggie L. Shaw |Frederick Locke
The investigational allogeneic chimeric antigen receptor (CAR) T-cell therapy cemacabtagene ansegedleucel (cema-cel; Allogene Therapeutics) is being evaluated in the ALPHA (NCT03939026) and ALPHA2 (NCT04416984) trials for relapsed/refractory large B-cell lymphoma, a type of non-Hodgkin lymphoma, and in the ALPHA3 trial (NCT06500273) in patients with a low disease burden who have received cema-cel as consolidation treatment in the first line. Continuing a discussion with Frederick L.
-
Mar 7, 2025 | 
ajmc.com | Maggie L. Shaw |Frederick Locke
In part 2 of this interview with Frederick L. Locke, MD, lead investigator on the phase 1 ALPHA (NCT03939026) and ALPHA2 (NCT04416984) trials of allogeneic chimeric antigen receptor T-cell therapy (CAR T) in relapsed/refractory large B-cell lymphoma (LBCL), explains why this hematologic cancer is such an attractive target for CAR T, specifically allogeneic, which uses healthy donor cells.
-
Feb 24, 2025 | 
ajmc.com | Maggie L. Shaw |Frederick Locke
Cemacabtagene ansegedleucel (cema-cel; Allogene Therapeutics) has robust data that reinforce its durability, effectiveness, and safety as an allogeneic chimeric antigen receptor (CAR) T-cell therapy for patients who have relapsed/refractory large B-cell lymphoma, a type of non-Hodgkin lymphoma.
-
Jan 17, 2024 | 
nature.com | Frederick Locke |Nicolaus Kröger
AbstractThe phase 3 ZUMA-7 trial in second-line large B cell lymphoma demonstrated superiority of anti-CD19 CAR T cell therapy (axicabtagene ciloleucel (axi-cel)) over standard of care (SOC; salvage chemotherapy followed by hematopoietic transplantation) (NCT03391466). Here, we present a prespecified exploratory analysis examining the association between pretreatment tumor characteristics and the efficacy of axi-cel versus SOC.
-
Dec 26, 2023 | 
onclive.com | Frederick Locke
Dr Jain on the Importance of Novel Therapies in Pediatric Patients With Bleeding DisordersZanubrutinib Favored Over Bendamustine/Rituximab Combination Across Biomarker Subgroups in CLL/SLL Without del(17p)Acquired BTK and PLCG2 Mutations May Not Drive Progression After Zanubrutinib/Ibrutinib Treatment in Relapsed CLLResponses With Pirtobrutinib Remain High Despite Acquired Resistance in Relapsed CLL/SLL
-
Dec 5, 2023 | 
onclive.com | Frederick Locke
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer CareDr Habib on Developments in Palliative Care For Patients With CancerDr Boland on the Emergence of KRAS G12C Inhibitors in mCRCDr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
-
Aug 7, 2023 | 
targetedonc.com | Frederick Locke
Frederick Locke, MD, a medical oncologist and translational researcher in the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center, discusses the available chimeric antigen receptor (CAR) T-cell therapies available for patients with diffuse large B-cell lymphoma (DLBCL) and where off the shelf therapies like ALLO-501 and ALLO-501A fit in this treatment paradigm.
-
Jul 17, 2023 | 
targetedonc.com | Frederick Locke
Frederick Locke, MD, a medical oncologist and translational researcher in the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center, explains the allogeneic CD19-directed chimeric antigen receptor (CAR) T-cell therapies, ALLO-501 and ALLO-501A, and how the work. An investigation of ALLO-501 for the treatment of patients with large B-cell lymphoma is occurring in the phase 1 ALPHA study (NCT03939026), which aims to include 74 patients.
